Australia's largest stock trading and investment forum Australia's #1 stock forum

PAR

Click for more information

1.92%

25.5¢ paradigm biopharmaceuticals limited..

Please can you explain how TGA provisional approval is dependent...

First 15 Last

Share
Profile

Follow
Gan_Gans

2,084 Posts.

562

14/05/23

18:47

Post #: 67766117
Share

Originally posted by ceviche: ↑

Just wanting to level set expectations.
My understanding

TGA is not off the cards for an application, rather it is dependent on the EU accepting that there is evidence of pain relief. That is one dependency.
FDA haven't been specifically asked yet if PAR need to include DMOAD in the upcoming trial that would otherwise satisfy pain relief. If the FDA doesn't, then the FDA might approve a fast path to a pain relief label independent of a DMOAD label. If they do, then any separate pain relief label is pushed out perhaps to the point it isn't sought, which reflects on EU progress and so a TGA approach.

So it would be a good idea for PAR to clarify
1. Will they ask FDA if there is a separate fast path for pain relief and for DMOAD labelling?
2. Either way, how would the FDA like that to happen
3. When are they (PAR) going to clarify that for us

I asked.

Clarifying those questions will go a long way to underpinning the share price.
The market places a step jump value on first revenue, otherwise you have a unicorn.
I am very much in favour of getting some revenue asap without detracting from a lot later.

Expand

Please can you explain how TGA provisional approval is dependent on what the EMA says. This is entirely lost on me.

PAR Price at posting: $1.03 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

RCE

Recce's R327 found effective against E.coli during clinical trial

There are more pages in this discussion • 27 more messages in this thread...

First 15 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 25.5¢		Change -0.005(1.92%)		Mkt cap ! $89.19M

Open	High	Low	Value	Volume
27.0¢	27.0¢	25.5¢	$261.4K	990.7K

Buyers (Bids)

No.	Vol.	Price($)
1	9999	25.5¢

Sellers (Offers)

Price($)	Vol.	No.
26.0¢	9445	1

View Market Depth

No.	Vol.	Price($)
1	9999	0.255
5	259000	0.250
4	96000	0.245
9	261374	0.240
5	71970	0.235

Price($)	Vol.	No.
0.260	9445	1
0.275	44000	2
0.280	35900	3
0.285	6729	2
0.290	60000	2

Last trade - 16.10pm 28/06/2024 (20 minute delay)

PAR (ASX) Chart

SPONSORED BY